Antonini A, D’Onofrio V, Guerra A. New levodopa infusion systems for advanced Parkinson’s disease. touchREVIEWS Neurol. 2024;20(1):23–6.

Article  Google Scholar 

Aubignat M, Tir M. Continuous subcutaneous foslevodopa-foscarbidopa in Parkinson’s disease: a mini-review of current scope and future outlook. Mov Disord Clin Pract. 2024;11(10):1188–94.

Article  PubMed  PubMed Central  Google Scholar 

Ullah I, Wang X, Li H. Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms. Neurol Sci. 2024;45:2979–95.

Article  PubMed  Google Scholar 

AbbVie Inc. VYALEV™ (foscarbidopa and foslevodopa) injection, for subcutaneous use: US prescribing information. 2024. https://www.rxabbvie.com/pdf/vyalev_pi.pdf. Accessed 12 Mar 2025.

Fung VSC, Aldred J, Arroyo MP, et al. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: considerations for initiation and maintenance. Clin Park Relat Disord. 2024. https://doi.org/10.1016/j.prdoa.2024.100239.

Article  PubMed  PubMed Central  Google Scholar 

Schroter N, Sajonz BEA, Jost WH, et al. Advanced therapies in Parkinson’s disease: an individualized approach to their indication. J Neural Transm. 2024;131(11):1285–93.

Article  PubMed  Google Scholar 

Phokaewvarangkul O, Auffret M, Groppa S, et al. What was first and what is next in selecting device-aided therapy in Parkinson’s disease? Balancing evidence and experience. J Neural Transm. 2024;131:1307–20.

Article  PubMed  Google Scholar 

Poplawska-Domaszewicz K, Chaudhuri KR. Subcutaneous foslevodopa/foscarbidopa: a novel 24h delivery option for levodopa. Int Rev Mov Dis. 2024;7:63–79.

Google Scholar 

Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, et al. Subcutaneous levodopa: a new engine for the vintage molecule. Neurol Ther. 2024;13:1055–68.

Article  PubMed  PubMed Central  Google Scholar 

AbbVie Ltd. Produodopa (foslevodopa/foscarbidopa) 240 mg/ml + 12 mg/ml solution for infusion: summary of product characteristics. 2024. https://www.medicines.org.uk/emc/product/15213/smpc#about-medicine. Accessed 12 Mar 2025.

AbbVie Corporation. VYALEV™ foslevodopa/foscarbidopa solution: Canadian product monograph including patient medication information. 2023. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102649. Accessed 12 Mar 2025.

Medthority. Vyalev a continuous subcutaneous infusion for Parkinson's disease is now launched in Japan [media release]. 28 Jul 2023. https://www.medthority.com/news/2023/7/vyalev-a-continuous-subcutaneousinfusion-for-parkinsons-disease-is-now-launched-in-japan.-abbvie.

Rosebraugh M, Voight EA, Moussa EM, et al. Foslevodopa/foscarbidopa: a new subcutaneous treatment for Parkinson’s disease. Ann Neurol. 2021;90(1):52–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosebraugh M, Stodtmann S, Liu W, et al. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Parkinsonism Relat Disord. 2022;97:68–72.

Article  CAS  PubMed  Google Scholar 

Rosebraugh M, Liu W, Neenan M, et al. Foslevodopa/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Parkinsons Dis. 2021;11(4):1695–702.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han Y, Kalluri H, Jeong A, et al. Pharmacokinetics, safety and tolerability of foslevodopa/foscarbidopa following continuous subcutaneous infusion to arm, thigh and flank compared to abdomen in Parkinson’s disease patients [abstract no. 62]. Mov Disord. 2023;38(S1):S27.

Google Scholar 

Savaryn JP, Smith RL, Rosebraugh M, et al. Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel. Pharmacol Res Perspect. 2024;12(2):1–11.

Article  Google Scholar 

Rosebraugh M, Neenan M, Facheris M. Comparability of foslevodopa/foscarbidopa pharmacokinetics in healthy Asian and white participants. Clin Pharmacol Drug Dev. 2023;12(4):407–15.

Article  CAS  PubMed  Google Scholar 

Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21(12):1099–109.

Article  CAS  PubMed  Google Scholar 

Kern D, Hauser R, Kimber T, et al. Improvement of “on” and “off” times in patients with advanced Parkinson’s disease treated with foslevodopa/foscarbidopa: subgroup analyses from a phase 3 randomized study [abstract no. S30.007]. Neurology. 2024;102(17_Suppl_1).

Soileau M, Bronstein J, Harmer L, et al. Efficacy and safety of foslevodopa/foscarbidopa in people with Parkinson’s disease with and without care partner support [abstract no. 687 plus poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024.

Aldred J, Henriksen T, Bouchard M, et al. Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson’s disease [abstract no. 19]. Mov Disord. 2023;38(S1):S7-8.

Google Scholar 

Pahwa R, Soileau M, Standaert D, et al. Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa [abstract no. 754]. Mov Disord. 2022;37(S2):S346.

Google Scholar 

Soileau M, Aldred J, Antonini A, et al. Impact of foslevodopa/foscarbidopa on key clinical and patient reported outcomes in patients with aPD: responder analysis of two phase 3 clinical trials [abstract no. 776 plus poster]. Mov Disord. 2022;37(S2):S354–5.

Google Scholar 

Odin P, Kimura T, Santos-Garcia D, et al. Effect of continuous subcutaneous foslevodopa/foscarbidopa treatment on falls, posture and freezing of gait [abstract no. EPR-281]. Eur J Neurol. 2023;30(S1):312.

Google Scholar 

Malaty I, Vaou E, Hauser R, et al. Correlation between sleep and quality of life in people with Parkinson’s disease treated with continuous subcutaneous infusion of foslevodopa/foscarbidopa [abstract no. 657 plus poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024.

Chaudhuri K, Bouchard M, Freire-Alvarez E, et al. Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials [abstract no. 39]. Mov Disord. 2023;38(S1):S18.

Google Scholar 

Hauser R, Fung V, Kimber T, et al. Long-term safety and efficacy of foslevodopa/foscarbidopa in patients with advanced Parkinson’s disease: results from an ongoing phase 3 open‑label extension with up to 1 year follow-up [abstract no. 693-098 plus poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024.

Aldred J, Freire-Alvarez E, Amelin AV, et al. Continuous subcutaneous foslevodopa/foscarbidopa in Parkinson’s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther. 2023;12(6):1937–58.

Article  PubMed  PubMed Central  Google Scholar 

Bergquist F, Aldred J, Carroll C, et al. Long-term safety and efficacy for motor fluctuations and quality of life with foslevodopa/foscarbidopa in patients with advanced Parkinson’s disease: interim results from an ongoing open label extension [abstract no. 705]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024.

Chaudhuri KR, Facheris MF, Bergmans B, et al. Improved sleep correlates with improved quality of life and motor symptoms with foslevodopa/foscarbidopa. Mov Disord Clin Pract. 2024;11(7):861–6.

Article  PubMed  PubMed Central  Google Scholar 

Henriksen T, Martínez-Castrillo J, Huisman M, et al. Efficacy and safety of foslevodopa/foscarbidopa subcutaneous infusion in patients with prior deep brain stimulation [abstract no. EPR-074]. Eur J Neurol. 2023;30(S1):169–70.

Google Scholar 

Blaabjerg M, Liang T, Peckham E, et al. Improvement of troublesome dyskinesia in people with Parkinson’s disease treated with foslevodopa/foscarbidopa [abstract no. EPO-361]. Eur J Neurol. 2024;31(Suppl 1):210–1.

Google Scholar 

Aldred J, Henriksen T, Bouchard M, et al. Treatment patterns with long-term foslevodopa/foscarbidopa use in Parkinson’s disease [abstract no. 710 plus poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024.

Kern D, Isaacson S, Dhanani S, et al. Safety of foslevodopa/foscarbidopa during optimization and maintenance treatment: post hoc analysis of a phase 3, single-arm trial [abstract no. 74]. Mov Disord. 2023;38(S1):S32.

Google Scholar 

Odin P, Kimber T, Bergmans B, et al. Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation [abstract no. 102]. Mov Disord. 2023;38(S1):S43–4.

Google Scholar 

Schlachter L, Stodtmann S, Talapala S, et al. Foslevodopa/foscarbidopa subcutaneous infusion shows similar infusion site reaction severity score across range of infusion rates in patients with Parkinson’s disease [abstract no. 118]. Mov Disord. 2023;38(S1):S49.

Google Scholar 

Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248–66.

Article  CAS  PubMed  Google Scholar 

Brinker D, Smilowska K, Paschen S, et al. How to use the new European Academy of Neurology/Movement Disorder Society European section guideline for invasive therapies in Parkinson’s disease. Mov Disord Clin Pract. 2024;11(3):209–19.

Article  PubMed  PubMed Central  Google Scholar 

Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology/Movement Disorder Society—European section guideline on the treatment of Parkinson’s disease: I. Invasive therapies. Mov Disord. 2022;37(7):1360–74.

Article  PubMed  Google Scholar 

National Institute for Health and Care Excellence. Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms: technology appraisal guidance TA934. 2023. https://www.nice.org.uk/guidance/ta934/chapter/3-Committee-discussion. Accessed 12 Mar 2025.

Standaert D, Fasano A, Ory-Magne F, et al. Comparative-effectiveness of foscarbidopa/foslevodopa (LDp/CDp) versus oral therapies in advanced Parkinson’s disease: a propensity matched study [abstract no. 824 plus poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024.

Menza M, Dobkin RD, Marin H, et al. Sleep disturbances in Parkinson’s disease. Mov Disord. 2010;25(Suppl 1):S117–22.

PubMed  PubMed Central  Google Scholar 

Santos-Garcia D, Castro ES, de Deus FT, et al. Sleep problems are related to a worse quality of life and a greater non-motor symptoms burden in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2021;34(6):642–58.

Article  PubMed  Google Scholar 

Antonini A, Bergmans B, Kern DS, et al. Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson's disease treated with foslevodopa/foscarbidopa subcutaneous 24-hour infusion [poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2023.

Mendes-Bastos P, Simoes RM. Algorithm for managing infusion site adverse events caused by subcutaneous foslevodopa/foscarbidopa and other device-aided therapies for advanced Parkinson’s disease. Parkinsonism Relat Disord. 2024. https://doi.org/10.1016/j.parkreldis.2024.107185.

Article  PubMed  Google Scholar 

Soileau M, Jason A, Zach B, et al. Living with continuous subcutaneous infusion of foslevodopa/foscarbidopa for symptom management in advanced Parkinson's disease: a patient experience st